Phosphodiesterase-5 inhibitor and rat lung ischemia-reperfusion injury.

Abstract

To explore the protective effect of the phosphodiesterase-5 inhibitor, sildenafil, on lung ischemia-reperfusion injury, 30 rats were randomly divided into 3 groups of 10: a sham-operated group A, a lung ischemia-reperfusion injury group B, and a sildenafil preconditioned group C. A 0.1% sildenafil solution was administrated orally 2 h before establishing an in-vivo lung ischemia-reperfusion model in group C; 0.9% normal saline solution was used in the controls. The lung wet-to-dry ratio, malondialdehyde content, myeloperoxidase and nitric oxide synthase activity in groups B and C were significant higher than those in group A, while the partial pressure of oxygen in arterial blood and cyclic guanosine-3',5'-monophosphate content in groups B and C were significant lower than those in group A. Compared to group B, lung wet/dry ratio, malondialdehyde content, myeloperoxidase and nitric oxide synthase activity in group C were significantly lower, while arterial O(2) and cyclic guanosine-3',5'-monophosphate content in group C were significantly higher. The expected histological and cytological changes were significantly alleviated in group C. Oral preconditioning with sildenafil prevented rat lung ischemia-reperfusion injury and improved pulmonary function. The mechanisms of this effect might be prevention of cyclic guanosine monophosphate degradation and inhibition of nitric oxide synthase activity.

• Authors: Zhiyong Liu, Lei Fang
• Journal: Asian cardiovascular & thoracic annals (Asian Cardiovasc Thorac Ann) Vol. 20 Issue 1 Pg. 42-7 (Feb 2012) ISSN: 1816-5370 [Electronic] England
• PMID: 22371941 (Publication Type: Journal Article)

Chemical References

• Phosphodiesterase 5 Inhibitors
• Piperazines
• Purines
• Sulfones
• Malondialdehyde
• Sildenafil Citrate
• Peroxidase
• Nitric Oxide Synthase
• Cyclic GMP

Topics

• Alveolar Epithelial Cells (ultrastructure)
• Animals
• Cyclic GMP (analysis)
• Endothelium, Vascular (ultrastructure)
• Lung Diseases (drug therapy, metabolism, pathology)
• Male
• Malondialdehyde (metabolism)
• Nitric Oxide Synthase (metabolism)
• Peroxidase (metabolism)
• Phosphodiesterase 5 Inhibitors (therapeutic use)
• Piperazines (therapeutic use)
• Purines (therapeutic use)
• Rats
• Rats, Sprague-Dawley
• Reperfusion Injury (drug therapy, metabolism, pathology)
• Sildenafil Citrate
• Sulfones (therapeutic use)